122 related articles for article (PubMed ID: 36198262)
1. Clinical Significance of Eligibility Criteria Determined by the SPIRITS Trial in Patients with Advanced Gastric Cancer.
Satake S; Arigami T; Matsushita D; Okubo K; Shimonosono M; Sasaki K; Tsuruda Y; Tanabe K; Mori S; Yanagita S; Uenosono Y; Nakajo A; Kurahara H; Ohtsuka T
Oncology; 2023; 101(1):12-21. PubMed ID: 36198262
[TBL] [Abstract][Full Text] [Related]
2. Factors, Including Clinical Trial Eligibility, Associated with Induction of Third-Line Treatment for Advanced Gastric Cancer.
Ando T; Hosokawa A; Sakumura M; Motoo I; Kajiura S; Hirano K; Miwa T; Yokota T; Nakada N; Ueda Y; Ueda A; Tsukada K; Ogawa K; Nakaya A; Teramoto A; Nanjo S; Mihara H; Fujinami H; Fujii T; Yasuda I
Oncology; 2023; 101(1):59-68. PubMed ID: 36103845
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of Conversion Surgery for Gastric Cancer with Peritoneal Dissemination: A Retrospective Study.
Arigami T; Matsushita D; Okubo K; Sasaki K; Noda M; Kita Y; Mori S; Kurahara H; Yanagita S; Uenosono Y; Ishigami S; Ohtsuka T; Natsugoe S
Oncology; 2020; 98(11):798-806. PubMed ID: 32906117
[TBL] [Abstract][Full Text] [Related]
4. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
5. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination.
Okabe H; Ueda S; Obama K; Hosogi H; Sakai Y
Ann Surg Oncol; 2009 Dec; 16(12):3227-36. PubMed ID: 19777180
[TBL] [Abstract][Full Text] [Related]
6. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
7. A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer.
Arigami T; Matsushita D; Okubo K; Shimonosono M; Sasaki K; Tsuruda Y; Kita Y; Tanabe K; Mori S; Yanagita S; Uenosono Y; Nakajo A; Kurahara H; Ohtsuka T
Surg Today; 2022 Dec; 52(12):1721-1730. PubMed ID: 35543754
[TBL] [Abstract][Full Text] [Related]
8. [The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
Sugimoto N; Narahara H; Sakai D; Yamamoto S; Fumoto S; Yagi T; Imamura F; Iishi H; Tatsuta M
Gan To Kagaku Ryoho; 2009 Mar; 36(3):417-24. PubMed ID: 19295265
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance and efficacy of conversion surgery for patients with stage IV gastric cancer].
Zhu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1087-1092. PubMed ID: 30370504
[TBL] [Abstract][Full Text] [Related]
10. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
[TBL] [Abstract][Full Text] [Related]
11. A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06).
Okabe H; Hata H; Hosogi H; Ueda S; Ota S; Kinjo Y; Hoshino N; Hisamori S; Tsunoda S; Obama K; Sakai Y;
Ann Surg Oncol; 2019 Jun; 26(6):1779-1786. PubMed ID: 30767179
[TBL] [Abstract][Full Text] [Related]
12. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
14. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
Sato Y; Ohnuma H; Nobuoka T; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Shinya M; Katsuki S; Takahashi M; Maeda M; Okagawa Y; Naoki U; Kikuch S; Okamoto K; Miyamoto H; Shimada M; Takemasa I; Kato J; Takayama T
Gastric Cancer; 2017 May; 20(3):517-526. PubMed ID: 27553665
[TBL] [Abstract][Full Text] [Related]
15. Eligibility of Real-World Patients With Stage II and III Colon Cancer for Adjuvant Chemotherapy Trials.
Batra A; Kong S; Cheung WY
Clin Colorectal Cancer; 2020 Dec; 19(4):e226-e234. PubMed ID: 32636076
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
17. [Application of laparoscopic exploration combined with abdominal exfoliative cytology in the diagnosis and treatment of locally advanced gastric cancer].
Ding PA; Liu Y; Guo HH; Yang PG; Tian Y; Fan LQ; Tan BB; Li Y; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Feb; 23(2):170-176. PubMed ID: 32074798
[No Abstract] [Full Text] [Related]
18. Clinical significance of initial treatment for peritoneal lavage cytology-positive gastric cancer: outcomes according to treatment strategy.
Yago A; Haruta S; Ueno M; Ogawa Y; Shimoyama H; Ohkura Y; Udagawa H
World J Surg Oncol; 2022 Feb; 20(1):35. PubMed ID: 35168610
[TBL] [Abstract][Full Text] [Related]
19. Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy.
Chen L; Hao Y; Cong X; Zou M; Li S; Zhu L; Song H; Xue Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819829485. PubMed ID: 30760114
[TBL] [Abstract][Full Text] [Related]
20. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Bamias A; Tzannis K; Harshman LC; Crabb SJ; Wong YN; Kumar Pal S; De Giorgi U; Ladoire S; Agarwal N; Yu EY; Niegisch G; Necchi A; Sternberg CN; Srinivas S; Alva A; Vaishampayan U; Cerbone L; Liontos M; Rosenberg J; Powles T; Bellmunt J; Galsky MD;
Ann Oncol; 2018 Feb; 29(2):361-369. PubMed ID: 29077785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
